We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

FDA grants client first-time approval on insomnia drug

01 December 2011

Pharmaceutical and Biotechnology Alert

Hogan Lovells client Transcept Pharmaceuticals, Inc. announced on 23 November 2011 U.S. Food and Drug Administration (FDA) approval of Intermezzo® (zolpidem tartrate sublingual tablet) – the first drug product cleared by the FDA to treat patients suffering from middle-of-the-night insomnia.

Read "FDA grants client first-time approval on insomnia drug"


Loading data